Subpopulation of small-cell lung cancer cells expressing CD133 and CD87 show resistance to chemotherapy

Toshio Kubo, Nagio Takigawa, Masahiro Osawa, Daijiro Harada, Takashi Ninomiya, Nobuaki Ochi, Eiki Ichihara, Hiromichi Yamane, Mitsune Tanimoto, Katsuyuki Kiura

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

Tumors are presumed to contain a small population of cancer stem cells (CSCs) that initiate tumor growth and promote tumor spreading. Multidrug resistance in CSCs is thought to allow the tumor to evade conventional therapy. This study focused on expression of CD133 and CD87 because CD133 is a putative marker of CSCs in some cancers including lung, and CD87 is associated with a stem-cell-like property in small-cell lung cancer (SCLC). Six SCLC cell lines were used. The expression levels of CD133 and CD87 were analyzed by real-time quantitative reverse transcription-polymerase chain reaction and flow cytometry. CD133+/- and CD87+/- cells were isolated by flow cytometry. The drug sensitivities were determined using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay. Non-obese diabetic/severe combined immunodeficiency mice were used for the tumor formation assay. SBC-7 cells showed the highest expression levels of both CD133 and CD87 among the cell lines. CD133-/CD87-, CD133+/CD87-, and CD133-/CD87+ cells were isolated from SBC-7 cells; however, CD133+/CD87+ cells could not be obtained. Both CD133+/CD87- and CD133-/CD87+ subpopulations showed a higher resistance to etoposide and paclitaxel and greater re-populating ability than the CD133-/CD87- subpopulation. CD133+/CD87- cells contained more G0 quiescent cells than CD133-/CD87- cells. By contrast, CD133-/CD87- cells showed the highest tumorigenic potential. In conclusion, both CD133 and CD87 proved to be inadequate markers for CSCs; however, they might be beneficial for predicting resistance to chemotherapy.

Original languageEnglish
Pages (from-to)78-84
Number of pages7
JournalCancer Science
Volume104
Issue number1
DOIs
Publication statusPublished - Jan 2013

Fingerprint

Small Cell Lung Carcinoma
Drug Therapy
Neoplastic Stem Cells
Neoplasms
Flow Cytometry
Cell Line
Severe Combined Immunodeficiency
Multiple Drug Resistance
Etoposide
Paclitaxel
Reverse Transcription
Lung Neoplasms
Stem Cells
Polymerase Chain Reaction
Growth

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Subpopulation of small-cell lung cancer cells expressing CD133 and CD87 show resistance to chemotherapy. / Kubo, Toshio; Takigawa, Nagio; Osawa, Masahiro; Harada, Daijiro; Ninomiya, Takashi; Ochi, Nobuaki; Ichihara, Eiki; Yamane, Hiromichi; Tanimoto, Mitsune; Kiura, Katsuyuki.

In: Cancer Science, Vol. 104, No. 1, 01.2013, p. 78-84.

Research output: Contribution to journalArticle

Kubo, Toshio ; Takigawa, Nagio ; Osawa, Masahiro ; Harada, Daijiro ; Ninomiya, Takashi ; Ochi, Nobuaki ; Ichihara, Eiki ; Yamane, Hiromichi ; Tanimoto, Mitsune ; Kiura, Katsuyuki. / Subpopulation of small-cell lung cancer cells expressing CD133 and CD87 show resistance to chemotherapy. In: Cancer Science. 2013 ; Vol. 104, No. 1. pp. 78-84.
@article{1726e9fd15c1477a87f9fa57c0f3b2b3,
title = "Subpopulation of small-cell lung cancer cells expressing CD133 and CD87 show resistance to chemotherapy",
abstract = "Tumors are presumed to contain a small population of cancer stem cells (CSCs) that initiate tumor growth and promote tumor spreading. Multidrug resistance in CSCs is thought to allow the tumor to evade conventional therapy. This study focused on expression of CD133 and CD87 because CD133 is a putative marker of CSCs in some cancers including lung, and CD87 is associated with a stem-cell-like property in small-cell lung cancer (SCLC). Six SCLC cell lines were used. The expression levels of CD133 and CD87 were analyzed by real-time quantitative reverse transcription-polymerase chain reaction and flow cytometry. CD133+/- and CD87+/- cells were isolated by flow cytometry. The drug sensitivities were determined using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay. Non-obese diabetic/severe combined immunodeficiency mice were used for the tumor formation assay. SBC-7 cells showed the highest expression levels of both CD133 and CD87 among the cell lines. CD133-/CD87-, CD133+/CD87-, and CD133-/CD87+ cells were isolated from SBC-7 cells; however, CD133+/CD87+ cells could not be obtained. Both CD133+/CD87- and CD133-/CD87+ subpopulations showed a higher resistance to etoposide and paclitaxel and greater re-populating ability than the CD133-/CD87- subpopulation. CD133+/CD87- cells contained more G0 quiescent cells than CD133-/CD87- cells. By contrast, CD133-/CD87- cells showed the highest tumorigenic potential. In conclusion, both CD133 and CD87 proved to be inadequate markers for CSCs; however, they might be beneficial for predicting resistance to chemotherapy.",
author = "Toshio Kubo and Nagio Takigawa and Masahiro Osawa and Daijiro Harada and Takashi Ninomiya and Nobuaki Ochi and Eiki Ichihara and Hiromichi Yamane and Mitsune Tanimoto and Katsuyuki Kiura",
year = "2013",
month = "1",
doi = "10.1111/cas.12045",
language = "English",
volume = "104",
pages = "78--84",
journal = "Cancer Science",
issn = "1347-9032",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - Subpopulation of small-cell lung cancer cells expressing CD133 and CD87 show resistance to chemotherapy

AU - Kubo, Toshio

AU - Takigawa, Nagio

AU - Osawa, Masahiro

AU - Harada, Daijiro

AU - Ninomiya, Takashi

AU - Ochi, Nobuaki

AU - Ichihara, Eiki

AU - Yamane, Hiromichi

AU - Tanimoto, Mitsune

AU - Kiura, Katsuyuki

PY - 2013/1

Y1 - 2013/1

N2 - Tumors are presumed to contain a small population of cancer stem cells (CSCs) that initiate tumor growth and promote tumor spreading. Multidrug resistance in CSCs is thought to allow the tumor to evade conventional therapy. This study focused on expression of CD133 and CD87 because CD133 is a putative marker of CSCs in some cancers including lung, and CD87 is associated with a stem-cell-like property in small-cell lung cancer (SCLC). Six SCLC cell lines were used. The expression levels of CD133 and CD87 were analyzed by real-time quantitative reverse transcription-polymerase chain reaction and flow cytometry. CD133+/- and CD87+/- cells were isolated by flow cytometry. The drug sensitivities were determined using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay. Non-obese diabetic/severe combined immunodeficiency mice were used for the tumor formation assay. SBC-7 cells showed the highest expression levels of both CD133 and CD87 among the cell lines. CD133-/CD87-, CD133+/CD87-, and CD133-/CD87+ cells were isolated from SBC-7 cells; however, CD133+/CD87+ cells could not be obtained. Both CD133+/CD87- and CD133-/CD87+ subpopulations showed a higher resistance to etoposide and paclitaxel and greater re-populating ability than the CD133-/CD87- subpopulation. CD133+/CD87- cells contained more G0 quiescent cells than CD133-/CD87- cells. By contrast, CD133-/CD87- cells showed the highest tumorigenic potential. In conclusion, both CD133 and CD87 proved to be inadequate markers for CSCs; however, they might be beneficial for predicting resistance to chemotherapy.

AB - Tumors are presumed to contain a small population of cancer stem cells (CSCs) that initiate tumor growth and promote tumor spreading. Multidrug resistance in CSCs is thought to allow the tumor to evade conventional therapy. This study focused on expression of CD133 and CD87 because CD133 is a putative marker of CSCs in some cancers including lung, and CD87 is associated with a stem-cell-like property in small-cell lung cancer (SCLC). Six SCLC cell lines were used. The expression levels of CD133 and CD87 were analyzed by real-time quantitative reverse transcription-polymerase chain reaction and flow cytometry. CD133+/- and CD87+/- cells were isolated by flow cytometry. The drug sensitivities were determined using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay. Non-obese diabetic/severe combined immunodeficiency mice were used for the tumor formation assay. SBC-7 cells showed the highest expression levels of both CD133 and CD87 among the cell lines. CD133-/CD87-, CD133+/CD87-, and CD133-/CD87+ cells were isolated from SBC-7 cells; however, CD133+/CD87+ cells could not be obtained. Both CD133+/CD87- and CD133-/CD87+ subpopulations showed a higher resistance to etoposide and paclitaxel and greater re-populating ability than the CD133-/CD87- subpopulation. CD133+/CD87- cells contained more G0 quiescent cells than CD133-/CD87- cells. By contrast, CD133-/CD87- cells showed the highest tumorigenic potential. In conclusion, both CD133 and CD87 proved to be inadequate markers for CSCs; however, they might be beneficial for predicting resistance to chemotherapy.

UR - http://www.scopus.com/inward/record.url?scp=84872275911&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84872275911&partnerID=8YFLogxK

U2 - 10.1111/cas.12045

DO - 10.1111/cas.12045

M3 - Article

C2 - 23066953

AN - SCOPUS:84872275911

VL - 104

SP - 78

EP - 84

JO - Cancer Science

JF - Cancer Science

SN - 1347-9032

IS - 1

ER -